Optic nerve glioma primary prevention: Difference between revisions
Jump to navigation
Jump to search
Simrat Sarai (talk | contribs) No edit summary |
(Mahshid) |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 5: | Line 5: | ||
Effective measures for the primary prevention of optic nerve glioma include regular [[eye]] exams in patients with [[neurofibromatosis]] type 1. | Effective measures for the primary prevention of optic nerve glioma include regular [[eye]] exams in patients with [[neurofibromatosis]] type 1. | ||
==Primary Prevention== | ==Primary Prevention== | ||
Optic pathway glioma occurs in 15 percent of patients with [[neurofibromatosis]] 1. Regular eye exams may allow early diagnosis of these [[tumors]] before they cause symptoms. Ophthalmologic screening should include confrontation [[visual field]] testing, color vision testing, [[visual acuity]] testing, and assessment of [[pupils]], eyelids, irises, fundi, and extraocular motility. The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are [[screening]] investigations in asymptomatic patients.<ref name="pmid9207339">{{cite journal| author=Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al.| title=The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. | journal=JAMA | year= 1997 | volume= 278 | issue= 1 | pages= 51-7 | pmid=9207339 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9207339 }} </ref><ref name="pmid8915311">{{cite journal| author=Wolkenstein P, Frèche B, Zeller J, Revuz J| title=Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. | journal=Arch Dermatol | year= 1996 | volume= 132 | issue= 11 | pages= 1333-6 | pmid=8915311 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8915311 }} </ref> The optimal care for individuals with [[NF1]] aims at the symptomatic treatment and early detection of complications as they occur. Genetic counseling may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.<ref name="pmid10588837">{{cite journal| author=Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R| title=Neurofibromatosis type 1 growth charts. | journal=Am J Med Genet | year= 1999 | volume= 87 | issue= 4 | pages= 317-23 | pmid=10588837 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10588837 }} </ref> | *Optic pathway glioma occurs in 15 percent of patients with [[neurofibromatosis]] 1. Regular eye exams may allow early diagnosis of these [[tumors]] before they cause symptoms. | ||
*Ophthalmologic screening should include confrontation [[visual field]] testing, color vision testing, [[visual acuity]] testing, and assessment of [[pupils]], eyelids, irises, fundi, and extraocular motility. | |||
*The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are [[screening]] investigations in asymptomatic patients.<ref name="pmid9207339">{{cite journal| author=Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al.| title=The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. | journal=JAMA | year= 1997 | volume= 278 | issue= 1 | pages= 51-7 | pmid=9207339 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9207339 }} </ref><ref name="pmid8915311">{{cite journal| author=Wolkenstein P, Frèche B, Zeller J, Revuz J| title=Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. | journal=Arch Dermatol | year= 1996 | volume= 132 | issue= 11 | pages= 1333-6 | pmid=8915311 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8915311 }} </ref> | |||
*The optimal care for individuals with [[NF1]] aims at the symptomatic treatment and early detection of complications as they occur. [[Genetic counseling]] may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.<ref name="pmid10588837">{{cite journal| author=Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R| title=Neurofibromatosis type 1 growth charts. | journal=Am J Med Genet | year= 1999 | volume= 87 | issue= 4 | pages= 317-23 | pmid=10588837 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10588837 }} </ref> | |||
==References== | ==References== | ||
| Line 14: | Line 17: | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Ophthalmology]] | [[Category:Ophthalmology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Ophthalmology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 14:48, 27 November 2017
|
Optic nerve glioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Optic nerve glioma primary prevention On the Web |
|
American Roentgen Ray Society Images of Optic nerve glioma primary prevention |
|
Risk calculators and risk factors for Optic nerve glioma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Effective measures for the primary prevention of optic nerve glioma include regular eye exams in patients with neurofibromatosis type 1.
Primary Prevention
- Optic pathway glioma occurs in 15 percent of patients with neurofibromatosis 1. Regular eye exams may allow early diagnosis of these tumors before they cause symptoms.
- Ophthalmologic screening should include confrontation visual field testing, color vision testing, visual acuity testing, and assessment of pupils, eyelids, irises, fundi, and extraocular motility.
- The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are screening investigations in asymptomatic patients.[1][2]
- The optimal care for individuals with NF1 aims at the symptomatic treatment and early detection of complications as they occur. Genetic counseling may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.[3]
References
- ↑ Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE; et al. (1997). "The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2". JAMA. 278 (1): 51–7. PMID 9207339.
- ↑ Wolkenstein P, Frèche B, Zeller J, Revuz J (1996). "Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients". Arch Dermatol. 132 (11): 1333–6. PMID 8915311.
- ↑ Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R (1999). "Neurofibromatosis type 1 growth charts". Am J Med Genet. 87 (4): 317–23. PMID 10588837.